Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 07 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-2.65 Insider Own24.43% Shs Outstand46.34M Perf Week-12.43%
Market Cap74.09M Forward P/E- EPS next Y-2.55 Insider Trans0.02% Shs Float36.13M Perf Month-11.93%
Income-124.08M PEG- EPS next Q-0.79 Inst Own58.23% Short Float / Ratio11.41% / 10.27 Perf Quarter-35.15%
Sales0.00M P/S- EPS this Y-0.82% Inst Trans11.61% Short Interest4.12M Perf Half Y-58.11%
Book/sh1.98 P/B0.78 EPS next Y7.81% ROA-72.89% Target Price11.67 Perf Year-84.30%
Cash/sh2.96 P/C0.52 EPS next 5Y- ROE-104.56% 52W Range1.24 - 10.38 Perf YTD-81.21%
Dividend- P/FCF- EPS past 5Y-34.47% ROI-129.31% 52W High-85.06% Beta0.69
Dividend %- Quick Ratio4.14 Sales past 5Y-71.14% Gross Margin- 52W Low25.00% ATR0.17
Employees66 Current Ratio4.14 Sales Q/Q- Oper. Margin0.00% RSI (14)48.59 Volatility14.28% 11.01%
OptionableYes Debt/Eq0.03 EPS Q/Q-1.40% Profit Margin- Rel Volume1.28 Prev Close1.40
ShortableYes LT Debt/Eq0.01 EarningsNov 07 AMC Payout- Avg Volume401.59K Price1.55
Recom1.00 SMA20-0.90% SMA50-3.73% SMA200-40.90% Volume515,087 Change10.71%
Date Action Analyst Rating Change Price Target Change
Sep-15-22Initiated JMP Securities Mkt Outperform $17
May-05-22Downgrade Credit Suisse Outperform → Neutral $35 → $5
Mar-21-22Initiated H.C. Wainwright Buy $25
Oct-15-21Resumed BTIG Research Buy $68
Jun-28-21Initiated ROTH Capital Buy $75
May-05-21Resumed Credit Suisse Outperform $68
Apr-26-21Resumed Credit Suisse Outperform $68
Jan-11-21Initiated JP Morgan Overweight $45
Jan-11-21Initiated Jefferies Buy $51
Jan-11-21Initiated Credit Suisse Outperform $49
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-30-23 08:00AM
Nov-28-23 08:00AM
Nov-12-23 09:24AM
04:01PM Loading…
Nov-07-23 04:01PM
Nov-06-23 04:05PM
Oct-12-23 07:30AM
Oct-10-23 07:30AM
Sep-06-23 08:00AM
Aug-03-23 04:01PM
Aug-02-23 11:31AM
Aug-01-23 04:01PM
Jul-25-23 08:00AM
07:09AM Loading…
Jul-07-23 07:09AM
Jun-26-23 08:00AM
May-31-23 08:00AM
May-11-23 04:01PM
May-08-23 04:05PM
May-04-23 08:00AM
Apr-29-23 09:29AM
Mar-31-23 06:36AM
Mar-27-23 07:12AM
Mar-24-23 11:31AM
Mar-23-23 04:05PM
Mar-16-23 08:00AM
Feb-27-23 08:07AM
Feb-23-23 08:00AM
Jan-25-23 07:10AM
08:00AM Loading…
Jan-10-23 08:00AM
Dec-29-22 04:05PM
Dec-22-22 08:00AM
Dec-08-22 08:54AM
Dec-01-22 09:55AM
Nov-15-22 09:55AM
Nov-11-22 08:38AM
Nov-08-22 08:00AM
Nov-04-22 11:15AM
Nov-03-22 04:01PM
Oct-27-22 08:00AM
Sep-23-22 09:15AM
Sep-21-22 10:14AM
Sep-12-22 10:08AM
Aug-18-22 06:39AM
Aug-09-22 07:25PM
Aug-03-22 08:00AM
Aug-02-22 08:00AM
Jun-04-22 08:12AM
Jun-01-22 04:05PM
May-04-22 04:01PM
Apr-08-22 08:00AM
Mar-01-22 06:00AM
Feb-07-22 05:38PM
Jan-10-22 04:05PM
Dec-21-21 09:00AM
Dec-11-21 06:34AM
Nov-15-21 05:09PM
Oct-04-21 10:56AM
Sep-29-21 08:03AM
Sep-12-21 08:49AM
Aug-13-21 05:54PM
Jun-14-21 02:03AM
May-12-21 06:26PM
Mar-16-21 01:59AM
Dec-18-20 04:00PM
Dec-16-20 05:34PM
Dec-15-20 07:59PM
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCBRINN SYLVIADirectorSep 08Buy2.542,0005,08011,125Sep 13 06:55 PM
SHORT JAY M PHDChief Executive OfficerMar 29Buy2.4740,800100,8621,412,387Mar 30 07:17 PM
Vasquez ChristianSee RemarksMar 28Buy2.4020,00047,970102,709Mar 29 05:20 PM
MCBRINN SYLVIADirectorDec 19Buy8.333,70030,8139,125Dec 19 05:41 PM